Pharvaris N.V.
PHVS
Updated: 23/09/2026, 10:07:07
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in phase 3 trials for treatment and prophylaxis of HAE attacks; and extended-release tablet and immediate-release capsule formulation of deucrictibant. Pharvaris N.V. was incorporated in 2015 and is headquartered in Zug, Switzerland.
No summaries found.
- Share price
- $35.20
- Market cap
- $2.46B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Berndt Modig
- Employees
- 148
- IPO date
- 04/02/2021
- Beta
- -2.324
- Last dividend
- $0.00
- Day range
- $34.91 – $36.19
- 52-week range
- $20.65 – $43.25
- 1-day performance
- -2.28%
- 1-year performance
- 70.46%
- Current drawdown (1Y)
- -18.61%
- CIK
- 0001830487
- CUSIP
- N/A
- ISIN
- NL00150005Y4
- Created
- 07/12/2025, 05:45:37
- Last update
- 23/09/2026, 10:07:07
Track Pharvaris N.V. with an AI analyst
See which prediction-market events move PHVS, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026
GlobeNewsWire • STOCK • 29/05/2026, 08:50:00
Pharvaris N.V. (PHVS) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Seeking Alpha • STOCK • 13/05/2026, 17:10:45
UBS Group AG (NYSE: UBS) Analyst Sets Bullish Price Target for Pharvaris (NASDAQ: PHVS)
Market Data • Market Data • 13/05/2026, 13:11:25
Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares
GlobeNewsWire • STOCK • 11/05/2026, 18:15:00
Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares
GlobeNewsWire • STOCK • 08/05/2026, 08:00:00
Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference
GlobeNewsWire • STOCK • 20/04/2026, 08:50:00
Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
GlobeNewsWire • STOCK • 02/04/2026, 08:50:00
Does Pharvaris (PHVS) Have the Potential to Rally 59.93% as Wall Street Analysts Expect?
Zacks Investment Research • STOCK • 01/04/2026, 12:55:29
Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology
GlobeNewsWire • STOCK • 20/03/2026, 07:50:00
Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology
GlobeNewsWire • STOCK • 11/03/2026, 07:50:00
Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026
GlobeNewsWire • STOCK • 02/03/2026, 07:50:00